Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™ seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha March 2019 insight

BOTOX® (onabotulinumtoxinA)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image71

FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity

Thu March 7, 2019 8:00 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, March 7, 2019 /PRNewswire/ -- Allergan plc (AGN)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image72

 Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

Wed March 6, 2019 5:30 PM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image73

Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

Wed March 6, 2019 5:30 PM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)

human leukocyte antigen or HLA type with Bria-IMT’s cell line

human leukocyte antigen or HLA type with Bria-IMT’s cell line

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image74

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire

Thu March 7, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK 

fifth Breakthrough Therapy Designation (BTD) to venetoclax,

human leukocyte antigen or HLA type with Bria-IMT’s cell line

fifth Breakthrough Therapy Designation (BTD) to venetoclax,

image75

 AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients

Thu March 7, 2019 8:46 AM|PR Newswire|About: ABBV 

Amgen (AMGN)

human leukocyte antigen or HLA type with Bria-IMT’s cell line

fifth Breakthrough Therapy Designation (BTD) to venetoclax,

Amgen Announces 2019 Second Quarter Dividend

Thu March 7, 2019 4:05 PM|PR Newswire|About: AMGN

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (AMGN

seeking biotech alpha March 2019 insight

corrector VX-445, tezacaftor and ivacaftor

MitraClip, HeartMate 3, CardioMEMS and XIENCE

corrector VX-445, tezacaftor and ivacaftor

image76

CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

Wed March 6, 2019 8:00 AM|Business Wire|About: VRTX 

XOFLUZA™ (baloxavir marboxil)

MitraClip, HeartMate 3, CardioMEMS and XIENCE

corrector VX-445, tezacaftor and ivacaftor

FDA Accepts Genentech’s Supplemental New Drug Application for XOFLUZA (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications

Wed March 6, 2019 1:00 AM|Business Wire|About: RHHBY 

Array BioPharma Inc. (ARRY)

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg)

MitraClip, HeartMate 3, CardioMEMS and XIENCE

image78

Array BioPharma Inc. 2019 Q2 - Results - Earnings Call Slides

Feb. 5, 2019 1:43 PM ET  | About: Array BioPharma Inc. (ARRY) 

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg)

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg)

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg)

image79

Gilead's Descovy on par with Truvada for preventing HIV infection

Mar. 6, 2019 3:26 PM ET|About: Gilead Sciences, Inc. (GILD)|By: , SA News Editor 

seeking biotech alpha March 2019 insight

Fedratinib is a highly selective JAK2 inhibitor

Fedratinib is a highly selective JAK2 inhibitor

Fedratinib is a highly selective JAK2 inhibitor

image81

U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

Tue March 5, 2019 7:30 AM|Business Wire|About: CELG 

Emgality® (galcanezumab-gnlm)

Fedratinib is a highly selective JAK2 inhibitor

Fedratinib is a highly selective JAK2 inhibitor

image82

 Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults

Tue March 5, 2019 6:45 AM|PR Newswire|About: LLY 

Alinity ci-series

Fedratinib is a highly selective JAK2 inhibitor

SPRAVATO (esketamine) CIII Nasal Spray for Adults

image83

Abbott's Latest Diagnostics Technology, Alinity, Selected by Regional Medical Laboratory, Inc. to Deliver Benefits to Hospitals and Patients

Tue March 5, 2019 9:00 AM|PR Newswire|About: ABT 

immune tolerance therapy

SPRAVATO (esketamine) CIII Nasal Spray for Adults

Sarepta Therapeutics, Inc. (SRPT)

image85

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

Tue March 5, 2019 10:05 AM|PR Newswire|About: PFE

CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance

Sarepta Therapeutics, Inc. (SRPT)

SPRAVATO (esketamine) CIII Nasal Spray for Adults

Sarepta Therapeutics, Inc. (SRPT)

image86

 Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock

Tue March 5, 2019 7:32 PM|GlobeNewswire|About: SRPT 

seeking biotech alpha March 2019 insight

Cosentyx® 300mg (secukinumab)

Humalog® (insulin lispro injection 100 units/mL)

Humalog® (insulin lispro injection 100 units/mL)

 Novartis' Cosentyx shows positive effect in Chinese psoriasis patients

Mar. 4, 2019 7:27 AM ET|About: Novartis AG (NVS)|By: , SA News Editor  

Humalog® (insulin lispro injection 100 units/mL)

Humalog® (insulin lispro injection 100 units/mL)

Humalog® (insulin lispro injection 100 units/mL)

image87

Lilly to Introduce Lower-Priced Insulin

Mon March 4, 2019 6:30 AM|PR Newswire|About: LLY 

KEYTRUDA® (pembrolizumab)

Humalog® (insulin lispro injection 100 units/mL)

KEYTRUDA® (pembrolizumab)

image88

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Mon March 4, 2019 6:45 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada

BXCL701, Nektar’s NKTR-214 and avelumab

BXCL701, Nektar’s NKTR-214 and avelumab

BXCL701, Nektar’s NKTR-214 and avelumab

image91

BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer

Mon March 4, 2019 8:00 AM|GlobeNewswire|About: BTAI, NKTR, PFE

Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer (PFE)) in pancreatic cancer

Merck KGaA, Darmstadt, Germany and Pfizer to supply checkpoint inhibitor immunotherapy, avelumab

NEW HAVEN, Conn., March 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI)

seeking biotech alpha March 2019 insight

PARP inhibitor Lynparza (olaparib)

PARP inhibitor Lynparza (olaparib)

PARP inhibitor Lynparza (olaparib)

image92

European advisory group backs AstraZeneca's Lynparza in breast cancer

Mar. 1, 2019 9:01 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor  

LORVIQUA® (lorlatinib)

PARP inhibitor Lynparza (olaparib)

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

image94

 Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Fri March 1, 2019 8:35 AM|Business Wire|About: PFE 

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

image95

 Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting

Fri March 1, 2019 4:40 PM|PR Newswire|About: NKTR 

Bausch Health Companies Inc. (BHC)

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

Flector® Patch (diclofenac epolamine topical patch)

image96

Synergy Pharma gets court OK to sell assets to Bausch; 

Mar. 1, 2019 7:14 PM ET|About: Bausch Health Companies Inc. (BHC)|By: , SA News Editor  

Flector® Patch (diclofenac epolamine topical patch)

NKTR-262, (TLR) 7/8 agonist, in combination w/ bempegaldesleukin* (NKTR-214 or bempeg),

Flector® Patch (diclofenac epolamine topical patch)

image97

 Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States

Fri March 1, 2019 4:08 PM|Business Wire|About: TEVA 

seeking biotech alpha March 2019 insight

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

image98

 BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older

Fri March 1, 2019 7:28 AM|PR Newswire|About: BMRN 

Fiasp® (insulin aspart injection) 100 u/mL

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

image99

Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents

Fri March 1, 2019 7:00 AM|PR Newswire|About: NVO 

SKYRIZI™ (risankizumab), an investigational interleukin-23 (IL-23) inhibitor

Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU)

SKYRIZI™ (risankizumab), an investigational interleukin-23 (IL-23) inhibitor

image100

 March 1, 2019

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis

 NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) 


 NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie 

ABBV, -0.21% 

ZynquistaTM* (sotagliflozin)

ZynquistaTM* (sotagliflozin)

SKYRIZI™ (risankizumab), an investigational interleukin-23 (IL-23) inhibitor

image101

 Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes

Fri March 1, 2019 8:01 AM|GlobeNewswire|About: SNY 

Dupixent® (dupilumab)

ZynquistaTM* (sotagliflozin)

Dupixent® (dupilumab)

image102

 Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication

Fri March 1, 2019 8:14 AM|GlobeNewswire|About: SNY 

Lorviqua (lorlatinib)

ZynquistaTM* (sotagliflozin)

Dupixent® (dupilumab)

image103

European advisory group backs Pfizer's lorlatinib for certain type of lung cancer

Mar. 1, 2019 8:26 AM ET|About: Pfizer Inc. (PFE)|By: , SA News Editor  

seeking biotech alpha February 2019 insight

CENTOGENE announced a 12-month strategic collaboration with Sarepta Therapeutics, Inc. (SRPT)

CENTOGENE announced a 12-month strategic collaboration with Sarepta Therapeutics, Inc. (SRPT)

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics

Thu February 28, 2019 9:00 AM|Business Wire|About: SRPT 

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

image106

Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

Wed February 27, 2019 4:35 PM|PR Newswire|About: NKTR

SAN FRANCISCO, Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR

NovoCure (NVCR)

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

Sangamo Therapeutics, Inc. (SGMO)

image107

NovoCure's (NVCR) CEO Asaf Danziger on Q4 2018 Results - Earnings Call Transcript

Feb. 28, 2019 1:32 PM ET  | About: NovoCure (NVCR) 

Sangamo Therapeutics, Inc. (SGMO)

immuno-oncology candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist

Sangamo Therapeutics, Inc. (SGMO)

image108

 Sangamo Q4 top line up 105%

Feb. 28, 2019 4:09 PM ET|About: Sangamo Therapeutics, ... (SGMO)|By: , SA News Editor 

Sangamo Therapeutics (NASDAQ:SGMO) Q4 results ($M): Revenues: 26.8 (+104.6%); Collaborations: 26.7 (+107.0%).


Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

Thu February 28, 2019 4:01 PM|PR Newswire|About: SGMO 

https://seekingalpha.com/pr/17429195-sangamo-therapeutics-reports-fourth-quarter-full-year-2018-financial-results

seeking biotech alpha February 2019 insight

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

image109

 Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

Wed February 27, 2019 9:00 AM|GlobeNewswire|About: SRPT 

Tremfya(R)

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

image110

 MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

Wed February 27, 2019 8:45 AM|Accesswire|About: JNJ, MOR

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 27, 2019 / MorphoSys AG (MPSYF) (FSE: MOR) (NASDAQ: MOR)

Accurian(TM) RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.

MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, / Beta-Sarcoglycanopathy

Accurian(TM) RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.

image111

 Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation

Wed February 27, 2019 7:00 AM|InPublic US|About: MDT 

Age Positively Initiative

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

Accurian(TM) RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.

image112

Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV

Tue February 26, 2019 4:30 PM|Business Wire|About: GILD 

Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL.

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

image113

 FDA expands indication for Soliqua® 100/33

Wed February 27, 2019 4:17 PM|PR Newswire|About: SNYPR Newswire

BRIDGEWATER, N.J., Feb. 27, 2019 /PRNewswire/

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine & orthopedic procedures

image114

 Medtronic Announces Approval and Launch of Japan's First DBM Bone Grafting Product for Spine and Orthopedic Procedures

Thu February 28, 2019 7:00 AM|InPublic US|About: MDT 

seeking biotech alpha February 2019 insight

CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy

diroximel fumarate (BIIB098), an oral fumarate for treatment of relapsing multiple sclerosis (MS)

CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy

image115

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

Mon February 25, 2019 8:00 AM|GlobeNewswire|About: CRSP, VRTX 

Behind the Seizure™ Program

diroximel fumarate (BIIB098), an oral fumarate for treatment of relapsing multiple sclerosis (MS)

CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy

image116

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

Tue February 26, 2019 7:30 AM|PR Newswire|About: BMRN, NVTA, XENEPR Newswire

SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ 

Thermo Fisher Scientific's (NYSE:TMO) Oncomine Dx Test CDx System

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

diroximel fumarate (BIIB098), an oral fumarate for treatment of relapsing multiple sclerosis (MS)

image118

 Expanded use for Thermo Fisher CDx test OK'd in Japan

Feb. 26, 2019 9:18 AM ET|About: Thermo Fisher Scientif... (TMO)|By: , SA News Editor 

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

image119

Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)

Tue February 26, 2019 10:00 AM|InPublic US|About: MDT 

LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38%

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

Resolute Drug-Eluting Stent (DES) platform (including Resolute Onyx(TM) & Resolute Integrity(TM) DES

image120

FDA OKs new formulation of Bausch Health's Lotemax

Feb. 25, 2019 7:21 AM ET|About: Bausch Health Companie... (BHC)|By: , SA News Editor  

seeking biotech alpha February 2019 insight

Brilinta (ticagrelor)

Roche to acquire Spark Therapeutics for $114.50 per share

2 (AMGN) patents on Repatha (evolocumab), antibodies on PCSK9 & reduce LDL-C

image123

AstraZeneca's Brilinta reduced CV risk in late-stage study

Feb. 25, 2019 7:31 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor 

2 (AMGN) patents on Repatha (evolocumab), antibodies on PCSK9 & reduce LDL-C

2 (AMGN) patents on Repatha (evolocumab), antibodies on PCSK9 & reduce LDL-C

2 (AMGN) patents on Repatha (evolocumab), antibodies on PCSK9 & reduce LDL-C

Amgen prevails in PCSK9 patent dispute with Regeneron and Sanofi

Feb. 25, 2019 8:09 PM ET|About: Amgen Inc. (AMGN)|By: , SA News Editor  

seeking biotech alpha February 2019 insight

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

image126

Merck to Acquire Immune Design

Thu February 21, 2019 6:45 AM|Business Wire|About: IMDZ, MRK 

Agilent Technologies Inc. (A)

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

image127

 Feb. 20, 2019 4:24 PM ET|About: Agilent Technologies Inc. (A)A$78.56 1.04 1.34%Agilent Technologies, Inc.Designs, manufactures and markets measurement and monitoring instruments52 Week Range60.42 - 78.80Market Cap.24.95BMore »(45,086 followers)|By: , SA News Editor 

Agilent (NYSE:A) fiscal Q1 results ($M): Revenue: 1,284 (+6.0%).

Net income: 504 (+257.5%); non-GAAP net income: 244 (+13.0%); EPS: 1.57 (+258.6%); non-GAAP EPS: 0.76 (+15.2%).

sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC)

Merck (MRK), known as MSD outside the United States and Canada, and Immune Design (IMDZ)

sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC)

image128

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

Wed February 20, 2019 5:05 PM|GlobeNewswire|About: IMMUGlobeNewswire

MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), (NASDAQ: IMMU) (“Immunomedics” or the “Company”),

U.S. healthcare spending to rise 5.5% per annum over next decade

U.S. healthcare spending to rise 5.5% per annum over next decade

U.S. healthcare spending to rise 5.5% per annum over next decade

image130

U.S. healthcare spending to rise 5.5% per annum over next decade

Feb. 21, 2019 7:14 AM ET|About: AbbVie Inc. (ABBV)|By: , SA News Editor 

FreeStyle® Libre flash glucose monitoring system

U.S. healthcare spending to rise 5.5% per annum over next decade

U.S. healthcare spending to rise 5.5% per annum over next decade

image131

 New Real-World Evidence Analysis of Nearly Half a Million FreeStyle® Libre System Users Shows Higher Rates of Scanning Improves Glucose Control

Thu February 21, 2019 9:40 AM|PR Newswire|About: ABT 


Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults

 Yogish C Kudva Andrew J Ahmann Richard M Bergenstal James R Gavin, IIIDavida F Kruger L Kurt Midyett Eden Miller Dennis R Harris 

 Journal of the Endocrine Society, Volume 2, Issue 12, 1 December 2018, Pages 1320–1337,https://doi.org/10.1210/js.2018-00294 

https://academic.oup.com/jes/article/2/12/1320/5181247

seeking biotech alpha February 2019 insight

Bristol-Myers Squibb C... (BMY)

Abbott (ABT) & Novo Nordisk (NVO)

Bristol-Myers Squibb C... (BMY)

image134

 Bristol-Myers sees earnings of $20B+ in 2025 after Celgene tie-up

Feb. 20, 2019 9:46 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor 

Bausch Health Companies Inc. (BHC)

NASH BIOTECHS AN OVERVIEW ON NASH DISEASE AND FUTURE TREATMENTS - G Divry

NASH BIOTECHS AN OVERVIEW ON NASH DISEASE AND FUTURE TREATMENTS - G Divry

 Bausch Health Companies Inc. 2018 Q4 - Results - Earnings Call Slides

Feb. 20, 2019 10:00 AM ET|28 comments  | About: Bausch Health Companies Inc. (BHC) 

NASH BIOTECHS AN OVERVIEW ON NASH DISEASE AND FUTURE TREATMENTS - G Divry

NASH BIOTECHS AN OVERVIEW ON NASH DISEASE AND FUTURE TREATMENTS - G Divry

NASH BIOTECHS AN OVERVIEW ON NASH DISEASE AND FUTURE TREATMENTS - G Divry

2019, THE NASH LANDSCAPE

UPDATED the 20 of february 2019

 G Divry 



 Intercept Pharmaceuticals Investors Strap In for a Wild Ride

Top-line data from the Regenerate trial cleared an important hurdle, but the race to launch the first NASH treatment isn't over yet.

Cory Renauer

 Feb 20, 2019 at 10:18PM
https://www.fool.com/investing/2019/02/20/intercept-pharmaceuticals-investors-strap-in-for-a.aspx

seeking biotech alpha February 2019 insight

ZIRABEV™ (bevacizumab)

Ochsner Health System, Louisiana’s largest non-profit academic healthcare system & Pfizer Inc (PFE)

Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.

image136

Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*

Tue February 19, 2019 9:32 AM|Business Wire|About: PFE 

Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.

Ochsner Health System, Louisiana’s largest non-profit academic healthcare system & Pfizer Inc (PFE)

Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.

image137

U. S. FDA Grants Clearance for Ion by Intuitive

February 19, 2019 at 11:18 AM ESTPDF VersionFlexible robotic catheter helps physicians reach nodules in the peripheral lung

SUNNYVALE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq: ISRG)

Ochsner Health System, Louisiana’s largest non-profit academic healthcare system & Pfizer Inc (PFE)

Ochsner Health System, Louisiana’s largest non-profit academic healthcare system & Pfizer Inc (PFE)

Ochsner Health System, Louisiana’s largest non-profit academic healthcare system & Pfizer Inc (PFE)

image138

Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials

Tue February 19, 2019 10:30 AM|Business Wire|About: PFE 

NovoCure (NVCR)

ESPEROCT® (turoctocog alfa pegol, N8-GP)

ESPEROCT® (turoctocog alfa pegol, N8-GP)

image141

 NovoCure (NVCR) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 10, 2019 3:31 PM ET|1 comment | About: NovoCure (NVCR) 

seeking biotech alpha February 2019 insight

ALKS 4230, engineered interleukin-2 (IL-2) variant immunotherapy, w/ Clovis' PARP inhibitor Rubraca

ALKS 4230, engineered interleukin-2 (IL-2) variant immunotherapy, w/ Clovis' PARP inhibitor Rubraca

ALKS 4230, engineered interleukin-2 (IL-2) variant immunotherapy, w/ Clovis' PARP inhibitor Rubraca

image143

 Alkermes teams up with Clovis in cancer combo treatments

Feb. 19, 2019 8:27 AM ET|About: Alkermes plc (ALKS)|By: , SA News Editor 

Medtronic plc (MDT)

ALKS 4230, engineered interleukin-2 (IL-2) variant immunotherapy, w/ Clovis' PARP inhibitor Rubraca

Medtronic plc (MDT)

image144

 Medtronic plc 2019 Q3 - Results - Earnings Call Slides

Feb. 19, 2019 10:00 AM ET | About: Medtronic plc (MDT) 

Entrectinib

polatuzumab vedotin in combination with bendamustine plus Rituxan ® (rituximab)

Medtronic plc (MDT)

image145

 

Monday, Feb 18, 2019

FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib

South San Francisco, CA -- February 18, 2019 --

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

polatuzumab vedotin in combination with bendamustine plus Rituxan ® (rituximab)

polatuzumab vedotin in combination with bendamustine plus Rituxan ® (rituximab)

polatuzumab vedotin in combination with bendamustine plus Rituxan ® (rituximab)

image146

 

Monday, Feb 18, 2019

FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma

Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns
Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease

South San Francisco, CA -- February 18, 2019 --

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

seeking biotech alpha February 2019 insight

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

image148

Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

Sun February 17, 2019 6:45 PM|InPublic US|About: MDT 

galectin-3 inhibitor GR-MD-02 in NASH cirrhosis

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

image149

 November 5, 2018

Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting

NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT),

tanezumab

PRODIGY Results: a Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

YESCARTA™ (Axicabtagene Ciloleucel)

image150

 Lilly and Pfizer's tanezumab successful in late-stage back pain study

Feb. 19, 2019 7:06 AM ET|About: Eli Lilly and Company (LLY)|By: , SA News Editor  

YESCARTA™ (Axicabtagene Ciloleucel)

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

YESCARTA™ (Axicabtagene Ciloleucel)

image151

 Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy

Tue February 19, 2019 8:00 AM|Canada Newswire|About: GILD 

Personalized Closed Loop (PCL) insulin pump system

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

image152

 Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

(GLOBE NEWSWIRE via COMTEX) --DUBLIN - February 19, 2019 - Medtronic plc (NYSE:MDT)

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

REGENERATE, obeticholic acid (OCA) patients w/ liver fibrosis -nonalcoholic steatohepatitis (NASH)

image153

 Intercept up 23% premarket on positive OCA data

Feb. 19, 2019 7:43 AM ET|About: Intercept Pharmaceuticals (ICPT)|By: , SA News Editor  

seeking biotech alpha February 2019 insight

Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

image154

 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium

Fri February 15, 2019 3:15 PM|PR Newswire|About: NKTR 

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

image155

Non Alcoholic Steatohepatitis is an emerging disease with high prevalence in the world population ! 

In the coming years, the treatment of the disease will become a big challenge and a huge market . 

 Copyrights  -  G.Divry - NASHBIOTECHS.COM 

http://www.nashbiotechs.com./ 

selonsertib

NASH Directeur de la Publication : Géry DIVRY -Copyrights - G.Divry - NASHBIOTECHS.COM

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

image156

Gilead's selonsertib flunks late-stage NASH study

Feb. 11, 2019 5:00 PM ET|About: Gilead Sciences, Inc. (GILD)|By: , SA News Editor  

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

image157

 KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Sat February 16, 2019 5:00 PM|Business Wire|About: MRK 

Keytruda (pembrolizumab) 17th U.S. indication

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

FDA OKs expanded use for Merck's Keytruda

Feb. 16, 2019 10:13 AM ET|About: Merck & Co Inc. (MRK)|By: , SA News Editor 

 



Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets)

image158

 04OCT2018News

CLINICAL TRIALS

HUMAN TRIALS

Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study

 By PBR Staff Writer 

seeking biotech alpha February 2019 insight

darolutamide plus androgen deprivation therapy (ADT)

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

darolutamide plus androgen deprivation therapy (ADT)

image159

 Bayer's darolutamide extends survival in late-stage prostate cancer study

Feb. 14, 2019 4:57 PM ET|About: Bayer A.G. ADR (BAYRY)|By: , SA News Editor  

Opdivo (nivolumab) Plus Yervoy (ipilimumab)

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

darolutamide plus androgen deprivation therapy (ADT)

image160

 Bristol-Myers' Opdivo + Yervoy shows positive effect in mid-stage prostate cancer study

Feb. 14, 2019 4:28 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor    

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

image161

 Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

Thu February 14, 2019 4:01 PM|GlobeNewswire|About: SRPT 

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

image162

 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

Fri February 15, 2019 6:45 AM|Business Wire|About: MRK 

 The FDA has accepted under Priority Review status Merck's (NYSE:MRK) supplemental marketing application seeking approval for Keytruda (pembrolizumab) plus Pfizer's (NYSE:PFE) Inlyta (axitinib) for the treatment of advanced renal cell carcinoma in a first-line setting. 

CERC-301 is a selective NR2B-specific NMDA receptor antagonist

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

CERC-301 is a selective NR2B-specific NMDA receptor antagonist

image163

Cerecor Announces CERC-301 Granted U.S. Patent

Fri February 15, 2019 6:30 AM|GlobeNewswire|About: CERC, MRK

ROCKVILLE, Md., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC)

Eli Lilly and Company (LLY)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

CERC-301 is a selective NR2B-specific NMDA receptor antagonist

image164

Lilly Completes Acquisition of Loxo Oncology

Fri February 15, 2019 9:23 AM|PR Newswire|About: LLY, LOXO 

seeking biotech alpha February 2019 insight

AstraZeneca Group plc (AZN)

DPP-4 inhibitor Tradjenta (linagliptin)

Symdeko (tezacaftor/ivacaftor and ivacaftor)

image167

 Feb. 14, 2019 7:13 AM ET|About: 

AstraZeneca Group plc (AZN)AZN

$36.58 -0.62 -1.67%

AstraZeneca PLC Sponsored ADR

Engages in manufacturing of pharmaceutical products

52 Week Range32.69 - 41.77Market Cap.92.70B

By: , SA News Editor 

AstraZeneca (AZN) Q4 results: Revenues: $6,417M (+11.1%); Product Sales: $5,768M (+5.1%); Externalisation Revenue: $649M (+123.8%).

biotech development in South Carolina

Medtronic and Medical University of South Carolina

Medtronic and Medical University of South Carolina

image169

New federal award to promote biotech development in South Carolina

Leslie Cantu February 06, 2019 

Medtronic and Medical University of South Carolina

Medtronic and Medical University of South Carolina

Medtronic and Medical University of South Carolina

image170

Medtronic and Medical University of South Carolina Partner to Improve Patient Outcomes

Thu February 14, 2019 8:00 AM|InPublic US|About: MDT 

 

Value-Based Health Care Partnership Will Target
Acute Conditions and Chronic Diseases in South Carolina

DUBLIN and CHARLESTON, S.C. - February 14, 2019 - Medtronic plc (MDT) and the Medical University of South Carolina (MUSC)

seeking biotech alpha February 2019 insight

HeartWare™ HVAD™ System

Johnson & Johnson to acquire Auris Health for $3.4B

Johnson & Johnson to acquire Auris Health for $3.4B

image171

Medtronic Heart Pump is the First to Receive Health Canada Licence for Less-Invasive Implant Procedure

Wed February 13, 2019 7:30 AM|Canada Newswire|About: MDT 

Johnson & Johnson to acquire Auris Health for $3.4B

Johnson & Johnson to acquire Auris Health for $3.4B

Johnson & Johnson to acquire Auris Health for $3.4B

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

Wed February 13, 2019 9:00 AM|PR Newswire|About: JNJ 

CVS HealthHUB

Johnson & Johnson to acquire Auris Health for $3.4B

SPRAVATO™ (esketamine)

image172

 CVS HealthHUB design unveiled in Houston

Feb. 13, 2019 6:20 AM ET|About: CVS Health Corporation (CVS)|By: , SA News Editor 

SPRAVATO™ (esketamine)

Enable Membrane Protein (EMP) platform

SPRAVATO™ (esketamine)

image173

FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

If approved, SPRAVATOTM will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen’s 60-plus-year history and commitment to research that make a difference for people living with mental illnesses, including severe mood disorders

TITUSVILLE, N.J., February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson 

Enable Membrane Protein (EMP) platform

Enable Membrane Protein (EMP) platform

Enable Membrane Protein (EMP) platform

image174

Amgen teams up with Abilita Bio in drug discovery

Feb. 13, 2019 11:37 AM ET|About: Amgen Inc. (AMGN)|By: , SA News Editor 

Enable Membrane Protein (EMP) platform

Enable Membrane Protein (EMP) platform

Chinese, US scholars jointly develop AI model to improve diagnosis of sick children

  • Drawing on records of nearly 600,000 paediatric patients, the software diagnosed common childhood diseases with an 85 per cent accuracy rate

 

PUBLISHED : Wednesday, 13 February, 2019, 7:04pm

UPDATED : Wednesday, 13 February, 2019, 7:03pm

 SCMP TODAY: INTL EDITION 

seeking biotech alpha February 2019 insight

Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab)

Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab)

Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab)

image175

 Bristol-Myers Opdivo + Yervoy shows sustained benefit in late-stage RCC study

Feb. 12, 2019 7:04 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor  

DARZALEX (daratumumab)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

BAVENCIO (avelumab) + INLYTA (axitinib)

image178

FDA OKs split-dosing regimen for J&J's Darzalex

Feb. 12, 2019 8:14 AM ET|About: Johnson & Johnson (JNJ)|By: , SA News Editor  

Tangible® Hydra-PEG® Custom Contact Lens Coating Technology

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

 Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible® Hydra-PEG® Custom Contact Lens Coating Technology On Several Of Its Boston® Gas Permeable Lens Materials And Zenlens™ Family Of Scleral Lenses

Wed February 13, 2019 8:00 AM|Canada Newswire|About: BHC 

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

image179

 Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU

Mon February 11, 2019 5:02 PM|Business Wire|About: MRK